XML 25 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses:    
Research and development $ 7,778 $ 7,559
General and administrative 2,958 2,682
Total operating expenses 10,736 10,241
Loss from operations (10,736) (10,241)
Other (expense) income    
Change in fair value of warrant liabilities (507) (1,278)
Loss on issuance of pre-funded warrants 0 (578)
Gain on sale of equipment 0 3
Foreign exchange transaction gain 0 153
Interest income 210 150
Interest expense (176) (36)
Total other expense, net (473) (1,586)
Net loss (11,209) (11,827)
Other comprehensive loss:    
Foreign currency translation adjustment 31 (73)
Comprehensive loss $ (11,178) $ (11,900)
Net loss per common share, basic (in dollars per share) $ (0.87) $ (1.15)
Net loss per common share, diluted (in dollars per share) $ (0.87) $ (1.15)
Weighted average common shares and pre-funded warrants outstanding, basic (in shares) 12,950,574 10,273,925
Weighted average common shares and pre-funded warrants outstanding, diluted (in shares) 12,950,574 10,273,925